Kyle Doherty

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Experts break down emerging data for the use of quadruplet regimens in newly diagnosed multiple myeloma.

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

OQY-3258 (ESG401) showed preliminary efficacy in multiple breast cancer subtypes, including TNBC and HR+/HER2- breast cancer.

The FDA has granted orphan drug designation to the CAR T-cell therapy MB-105 in CD5-positive T-cell lymphoma.

The REZILIENT1 study of zipalertinib in pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations met its primary end point of ORR.

Felix Y. Feng, MD, a radiation oncologist and researcher at UCSF, died of cancer on December 10, 2024, at 48 years old.

Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.

The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.

Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.

China’s NMPA has approved isatuximab plus pomalidomide and dexamethasone in adult patients with pretreated multiple myeloma.

The FDA has set the PDUFA date for the 3-month, 21-mg variation of leuprolide mesylate in advanced prostate cancer for August 29, 2025.

The BLA for Dato-DXd in locally advanced or metastatic EGFR-mutated NSCLC has been accepted and granted priority review by the FDA.

Emiltatug ledadotin produced positive initial phase 1 data in breast, ovarian, and endometrial cancer, as well as adenoid cystic carcinoma type 1.

BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.

The phase 3 ARES trial of MaaT013 in third-line GI-aGVHD met its primary end point of GI-ORR at day 28.

The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.

Rebecca Arend, MD, and Kathryn Lyle, CRNP, discuss their approach to managing ocular and other treatment-related toxicities associated with mirvetuximab soravtansine.

Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.

The FDA released a draft guidance document detailing their interpretation of when a confirmatory clinical trial for an accelerated approval is underway.

Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.

Imetelstat plus ruxolitinib showed early tolerability and efficacy in patients with intermediate and high-risk myelofibrosis.

The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.

A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly every aspect of the multiple myeloma field, and he continues to push the boundaries of what is possible.

Since it's implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and other diseases expanded access to affordable medications by selling drugs at discounted prices to eligible centers.

A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.

A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.